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Avian influenza (AI) virus subtype H5N1 is a highly pathogenic virus that causes acute 
infection with high mortality in susceptible birds. Additionally, the virus can also cause 
lethal infection in human. Effective control of AI requires various strategies which 
comprises of vaccination, biosecurity, education, diagnostics and surveillance. The 
crucial objectives of AI control strategies are to prevent introduction of AI, ease the 
losses and total eradication of AI. Immune response against the Hemagglutinin (HA) 
protein and the Neuraminidase (NA) protein by the immune components results in 
protection against AI. Currently, several conventional and genetically engineered AI 
vaccines using recombinant technology has been developed and tested in experimental 
trials. However, its application in commercial chickens has not been studied thoroughly 
except for conventional and fowlpox virus based vaccines. Vaccination using DNA 
vaccines is an attractive approach to induce vaccine-induced immunity. On the other 
hand, DNA vaccine is relatively less immunogenic. Furthermore, several inoculations 
are required to induce strong vaccine-induced immunity. Different approaches such as 
ii 
 
adjuvants are available to enhance the immunogenicity of DNA vaccine. The objectives 
of this study were to construct and express the pcDNA3.1/H5, pcDNA3.1/N1 and 
pcDNA3.1/NP of H5N1 and to explore the adjuvancy role of Mycobacterial DNA 
binding Protein-1 (MDP1) in augmenting H5 DNA vaccine in inducing specific 
antibody response. Constructed pcDNA3.1/MDP1 plasmids encoding MDP1 was 
obtained from Osaka University, Japan. The complete genes of H5, N1 and NP gene of 
Malaysian H5N1 virus (A/Ck/Malaysia/5858/04) were cloned separately into 
pcDNA3.1+ vector. The orientation of the cloned fragments was verified by restriction 
mapping and DNA sequencing. The expression of protein of the cloned genes was 
evaluated by transfection of Vero cell lines followed by detection of bands of the 
expected sized using Western blotting analysis. The immunogenicity of the cloned H5 
DNA vaccine was tested in SPF chickens. The chickens were divided into 5 groups 
namely H5, H5+MDP1, pcDNA3.1, PBS and negative control. The constructed 
plasmids were injected intramuscularly to 10 days old chickens followed by two booster 
injections at 14 and 28 days. Bleeding via wing vein was conducted every week post 
immunization and the collected sera were analyzed using HI test. The HI test showed 
successful antibody production second week after immunization with an increase in 
antibody titers during the course of experiment in group inoculated with H5 and 
H5+MDP1. The result showed that the constructed DNA vaccines were able to induce 
the production of detectable antibody titer. Furthermore, spleen and muscle samples 
from chickens inoculated with H5 and H5+MDP1 expressed H5 RNA transcripts. 
However, the higher antibody titers in chickens inoculated with H5+MDP1 was not 
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statistically significant when compared with chickens inoculated with H5 alone. The 
highest HI titers for both groups never exceeded 16 HI unit.  
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Virus selesema burung jenis H5N1 adalah virus yang sangat patogenik yang  
menyebabkan jangkitan akut dan mengakibatkan kadar kematian yang tinggi terhadap 
spesis burung. Virus ini juga boleh mengakibatkan jangkitan yang membawa maut 
kepada manusia. Bagi mengawal penyakit selesema burung secara efektif, pelbagai 
strategi diperlukan yang melibatkan kesepakatan dari segi vaksinasi, keselamatan 
biologi, pendidikan, diagnostik dan pengawasan yang rapi. Beberapa objektif penting  
dalam strategi mengawal penyakit selesema burung ialah mengelak permulaan wabak 
penyakit, mengatasi kelemahan, dan membasmi penyakit ini sepenuhnya. Tindak balas 
imun terhadap protein Hemagglutinin (HA) dan protein Neuraminidase (NA) oleh 
komponen imun dapat memberi kan perlindungan daripada penyakit tersebut. Kini, 
terdapat beberapa vaksin konvensional dan vaksin rekombinan yang terhasil dengan 
menggunakan teknologi kejuruteraan genetik yang telah diuji secara ujian makmal 
namun pengaplikasiannya secara komersial terhadap ayam belum lagi dilakukan secara 
menyeluruh kecuali bagi vaksin konvensional dan vaksin rekombinan  berasaskan virus 
v 
 
fowlpox. Vaksinasi yang menggunakan vaksin DNA merupakan satu pendekatan 
menarik untuk mengaruh keimunan. Namun, vaksin DNA ini agak kurang imunogenik. 
Selain itu, beberapa inokulasi diperlukan untuk mengaruh keimunan yang kuat. 
Beberapa pendekatan berbeza seperti adjuvan boleh didapati dalam meningkatkan sifat 
imunogenik vaksin DNA. Objektif kajian ini adalah untuk meneroka peranan 
keadjuvanan  Protein Pengikat DNA – 1 Mikobakteria (MDP1) dalam meningkatkan 
keupayaan vaksin DNA H5 menghasilkan tindak balas antibodi, Plasmid 
pcDNA3.1/MDP1 yang mengkod MDP1 telah diperoleh dari Universiti Osaka, Jepun. 
Gen lengkap H5, N1 dan NP untuk virus H5N1 dari Malaysia (A/Ck/Malaysia/5858/04) 
telah diklonkan secara berasingan di dalam vektor pcDNA3.1+. Kedudukan fragmen 
yang diklonkan telah disahkan dengan pemetaan sekatan dan penjujukan DNA. 
Penghasilan protein bagi gen-gen yang telah diklonkan dinilai dengan transfeksi sel 
Vero, diikuti dengan pengesanan jalur yang telah ditentukan saiznya menggunakan 
analisis Blot Western. Sifat imunogenik vaksin DNA H5 yang diklonkan diuji dalam 
ayam SPF. Ayam dibahagikan kepada 5 kumpulan iaitu kumpulan H5, H5+MDP1, 
pcDNA3.1, PBS, dan kawalan. Plasmid yang dibangunkan telah disuntik secara 
intraotot pada ayam yang berumur 17 hari, diikuti dengan dua suntikan penggalak pada 
hari ke-14 dan ke-28 selepas imunisasi pertama. . Pendarahan pada vena kepak 
dilakukan setiap minggu dan serum yang dikumpulkan dianalisis menggunakan Ujian 
HI. Ujian HI menunjukkan kejayaan penghasilan antibodi pada minggu ke-2 imunisasi 
dengan peningkatan jumlah titer antibodi semasa ujian dijalankan terhadap kumpulan 
yang diinokulat dengan H5 dan H5+MDP1. Keputusan menunjukkan bahawa vaksin 
DNA yang dibangunkan berupaya menghasilkan titer antibodi yang dapat dikesan. 
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Selain itu, sampel limpa dan otot daripada ayam-ayam yang telah diinokulat dengan H5 
and H5+MDP1 menunjukkan transkrip RNA H5. Namun, jumlah titer antibodi  yang 
tinggi daripada ayam yang diinokulat dengan H5+MDP1 tidak signifikan secara statistik 
jika dibandingkan dengan ayam yang diinokulat dengan H5 sahaja. Titer HI yang 
tertinggi daripada kedua-dua kumpulan tidak melebihi 16.  
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Introduction 
 
 
Influenza virus can cause an acute, highly transmittable respiratory disease, which 
could result in high morbidity and mortality in both human and animals (Murphy & 
Webster 1996). In 1918, a pandemic of influenza H1N1 virus (Spanish flu) cause a 
loss of 100 million lives worldwide. More recently, the 1997 Hong Kong outbreak 
(H5N1) showed that avian influenza is still a potential threat to human, which is 
believed to be transmitted from infected birds. In that outbreak, 30% of the infected 
humans died, indicating that if avian influenza can be transmitted from human to 
human, there will be destructive consequences (Yuen et al. 1998, De Jong et al. 
1997). The Hong Kong outbreak of avian influenza H5N1 was controlled by 
slaughtering 1.5 million chickens, which cost more than 245 million dollars (HKD) 
in one month. Therefore, antivirals and vaccines are prospective solutions to avoid 
future outbreaks of avian influenza virus. Nonetheless, logistical restrictions will 
prevent widespread usage of antiviral agents in pandemics regions globally.   
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Currently, inactivated vaccines containing HA as the main component, are the 
common vaccines to prevent avian influenza. However, it requires large numbers of 
specific-pathogen-free embryonated chicken eggs and some 6 months to propagate 
(De Jong et al. 1997). On the other hand, this is not an ideal method to produce 
inactivated vaccine for highly pathogenic strains, as they kill the embryo shortly 
after propagation and require a high level of biosecurity to handle (Voeten et al. 
1999). Such vaccines had been successful in producing protective immunity against 
infections using homologous virus but failed in preventing the outbreaks of 
heterologous virus (Couch & Kasel 1983, Meyer et al. 1978, Hoskins et al. 1976). 
Presently, various vaccines against avian influenza H5N1 virus with different level 
of protective immunity, such as DNA plasmid-based vaccine, baculovirus 
recombinant H5 vaccine, fowl pox based H5 vaccine and reverse genetic H5 vaccine 
have been examined experimentally and/or available commercially (Govorkova et al. 
2006, Boyle et al. 2000, Kodihalli et al. 2000, Crawford et al. 1999, Ulmer et al. 
1993). 
 
Concurrent studies have revealed that DNA vaccines encoding HA, N1 and NP of 
influenza A virus can result in the development of protective immune response 
against influenza virus challenge in animals (Chen et al. 2005, Vecino et al. 2004, 
Chen et al. 2000, Johnson et al. 2000, Chen et al. 1999, Lunn et al. 1999, Kodihalli 
et al. 1999, Chen et al. 1998, Deck et al. 1997, Webster et al. 1994). In most cases, 
two or three doses of naked plasmid DNA can induce immune response to the 
pathogen (Davis 1997, Hinkula et al. 1997, Leitner et al. 1997, Wang et al. 1993). 
Nevertheless, other studies had shown that a single dose of DNA vaccine can trigger 
protective immunity, which demonstrated the high potential of DNA vaccines as an 
alternative to inactivated vaccines (Lodmell et al. 2003, Lima et al. 2003, Sullivan et 
al. 2003, Moraes et al. 2002, Konishi et al. 1998, Robinson et al. 1997). 
 
In order to improve release of the vaccine, the delivery and presentation to the host 
immune system, vaccines are frequently formulated with adjuvants. Adjuvants can 
augment both humoral and cellular responses of the host immune system (Vogel et 
al. 2000). In general, common adjuvants in use are aluminium and calcium salts, oil 
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emulsions, saponin, liposomes, microparticles, cytokines, polysaccharides, immune 
stimulating complexes (ISCOMS) and genetic adjuvants (Aucouturier et al. 2001). 
Genetic adjuvants comprised of plasmid vectors encoding specific cytokines, 
stimulatory molecules or ligands that improve the host immune response to the 
antigen via encoding cytokines or plasmid-encoded protein-activated cytokines 
(Lillehoj et al. 2005). 
 
Mycobacterial DNA binding protein 1 (MDP1) is a main cellular protein produced 
by Mycobacterium. It has nucleic acid binding activity and up-regulates the 
stationary and dormant state of Mycobacterium bovis. On the other hand, the protein 
also prevents macro-molecular bio-synthesis and therefore suppresses bacterial 
growth (Matsumoto et al. 2000). MDP1 can bind to glycosaminoglycans and laminin 
(Aoki et al. 2004). Glycosaminoglycans is an important element in the extracellular 
matrix as it plays a vital role in attaching mycobacteria to nonphagocytic cells, such 
as fibroblasts and epithelial cells (Menozzi et al. 1996), the latter being the main 
reservoirs of M. tuberculosis in healthy humans (Hernández-Pando et al. 2000). 
Prabhakar et al., in 1998, suggested that MDP1 is useful as an immunodominant Ag 
with a vital influence in host defense. MDP1 can augment the production of 
proinflammatory cytokines through a TLR9 dependent pathway, resulting in the 
stimulation of cellular and humoral responses (Hemmi et al. 2000, Krieg et al. 1995, 
Yamamoto et al. 1992) and significantly influence the immune response by inducing 
the secretion of IFN-γ (Cooper et al. 1993, Flynn et al. 1993). Prior to this study, 
MDP1 had been shown to be a potential DNA vaccine adjuvant in BCG, which  has 
a unique ability in blocking DNase activity, and consequently decreasing the amount 
of DNA necessary for vaccination (Matsumoto et al. 2005, Krieg 2002). 
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Immunologists have gained a large interest in the application of DNA vaccines in 
regulating the immune response of the host due to their numerous advantages. 
Hence, MDP1 may play an important role as a potential adjuvant to boost the 
immunotherapeutic effects of these vaccines (Klinman 2004, Halperin et al. 2003, 
Jahrsdorfer & Weiner 2003, Krieg 2002). 
 
The objective of this current study is to construct eukaryotic expression vector as 
DNA vaccines that are able to induce immune responses against H5N1 avian 
influenza virus in chicken and to determine whether the response can be augmented 
by co-administration of MDP1 gene as a genetic adjuvant. Thus, specific objectives 
of this study were: 
1. to construct eukaryotic DNA plasmids expressing H5, N1 and NP of 
Malaysian H5N1 (A/chicken/H5N1/5858/2004) 
2. to express the constructed DNA plasmids in cell culture system and 
3. to determine the ability of MDP1 in augmenting antibody responses in 
chickens following vaccination with the H5 based DNA vaccine . 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1   Influenza virus 
 
2.1.1   Structure of influenza virus 
 
The standard shape for influenza viruses is spherical and they are about 100nm in 
diameter but there are reports of observing them in different shapes and sizes (De 
jong 2000). Influenza viruses are enveloped single stranded RNA with negative 
polarity (ssRNA) (Geider et al. 1981). Influenza virus consists of Haemagglutinin 
(HA), Neuraminidase (NA), Nucleoprotein (NP), RNA polymerase subunits (PB1, 
PB2, PA), Matrix proteins (M1, M2) and Non-structural proteins (NS1, NS2) 
(Geider et al. 1981). 
 
HA and NA are distinct surface glycoproteins, there is about 450-500 of them on 
each virion and they protrude about 10-14 nm out of the virions surface. For each 
NA there is about 4-8 HA on the surface and therefore about 25-40% of the virion’s 
protein mass is due to HA and 5% to NA protein (De jong 2000, Geider et al. 1981). 
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PB1, PB2 and PA are three large proteins that bind to the nucleoprotein and their 
main role is to assist the RNA of virus to transcript and replicate. Matrix protein1 
(M1) has an important role in the morphology of virus as it covers the lipid envelope 
of the virus from underneath (Geider et al. 1981). Meanwhile, M2 is expressed in 
less abundance on the virion’s envelope as an ion channel (Geider et al. 1981).   
 
 
 
Figure 2.1: Structure of the influenza virus. The phospholipid surface has three 
different proteins, hemagglutinin (HA), neuraminidase (NA) and matrix protein 
(M2). The double layer phospholipid is from the infected host and makes the virions 
outer layer. The RNA segments and the rest of structural and non-structural proteins 
are enveloped in the bilayer lipid surface (Knipe et al. 2001) 
 
2.1.2   Taxonomic classification 
 
Influenza viruses are from the Orthomyxoviridae family (Wright 2002). They can be 
divided into three different genera called A, B and C based on two internal proteins 
named Nucleocapsid (NP) and Matrix proteins (M1 and M2). The different genera of 
influenza viruses have no cross-reactivity among themselves (Geider et al. 1981, 
Wright 2002). Sub-typing of influenza viruses is based on their surface 
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